Biotechnology

Yili Chuanning Bio

Yili Chuanning Bio released FY2026 Q1 earnings on April 22 During-Market (BJT), actual revenue CNY 1.094 B, actual EPS CNY 0.05

Yili Chuanning Bio FY2026 Q1 Earnings Release on April 23 During-Market BJT

Yili Chuanning Bio released FY2025 earnings on March 30 After-Market (BJT), actual revenue CNY 4.616 B (forecast CNY 4.709 B), actual EPS CNY 0.34 (forecast CNY 0.39)

Yili Chuanning Bio released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 1.18 B, actual EPS CNY 0.0699

Yili Chuanning Bio to Release FY2025 Annual Earnings on March 31, 2026 After-Market (BJT), Forecast Revenue CNY 4.709 B, EPS CNY 0.39

Yili Chuanning Bio released FY2025 9 Months Earnings on October 27 After-Market (BJT), actual revenue CNY 3.436 B, actual EPS CNY 0.2712

Yili Chuanning Bio released FY2025 Q3 earnings on October 27 After-Market BJT, actual revenue CNY 1.087 B, actual EPS CNY 0.0697

Yili Chuanning Bio to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Yili Chuanning Bio released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 1.052 B, actual EPS CNY 0.0714

Yili Chuanning Bio released FY2025 Semi-Annual Earnings on August 25 After-Market BJT, actual revenue CNY 2.349 B, actual EPS CNY 0.2

Yili Chuanning Bio to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Chuanning Biotech's ESG Rating Dropped to A

Explanation of Reasons for Chuan Ning Bio's Q1 Decline in Performance

Chuan Ning Bio's Stock Price Rises, Given Buy Rating by Minsheng Securities

Chuan Ning Biological Reports Strong 2024 but Q1 2025 Pressured

Yili Chuanning Bio released FY2025 Q1 earnings on April 28 During-Market BJT, actual revenue CNY 1.297 B, actual EPS CNY 0.13

Company's Three Categories of Intermediate Products Sales in Q1 and Outlook for the Year

Yili Chuanning Bio FY2025 Q1 Earnings Release on April 29 During-Market BJT

Yili Chuanning Bio released FY2024 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 1.302 B, actual EPS CNY 0.1497

Yili Chuanning Bio released FY2024 earnings on April 21 After-Market BJT, actual revenue CNY 5.758 B (forecast CNY 5.924 B), actual EPS CNY 0.63 (forecast CNY 0.65)

301301

Yili Chuanning Bio announced that its revenue for the third quarter was 1.087 billion yuan, a year-on-year decrease of 13.76%; net profit was 157 million yuan, a year-on-year decrease of 49.44%. Revenue for the first three quarters was 3.436 billion yuan, a year-on-year decrease of 22.90%; net profit was 611 million yuan, a year-on-year decrease of 43.17%

Zhitong

Yili Chuanning Bio: Net profit in the third quarter was 157 million yuan, a year-on-year decrease of 49.44%

According to the Zhitong Finance APP, Yili Chuanning Bio announced that the company has received the "Acceptance of Registration Notice" issued by the Association of Dealers. The Association of Dealers has agreed to accept the registration of the company's medium-term notes, with a registered amount of 1 billion yuan. The registration quota is valid for 2 years from the date of this notice

Yili Chuanning Bio has been approved to register 1 billion yuan medium-term notes

002422

KELUN PHARMA stated in an institutional research that the demand for the antibiotic sector is stabilizing. Despite price fluctuations, the company has a clear cost advantage. Yili Chuanning Bio expects a significant decline in overall performance this year compared to last year, affected by the market price of penicillin. With the arrival of the peak season in the fourth quarter, performance is expected to improve, and the volume of synthetic biology products in 2026 and the rebound in penicillin prices will bring greater improvement potential

KELUN PHARMA

KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve

On August 25th, Yili Chuanning Bio disclosed its semi-annual report, stating that the company achieved operating revenue of 2.349 billion yuan in the first half of the year, a year-on-year decrease of 26.50%; the net profit attributable to shareholders of the listed company was 455 million yuan, down from 766 million yuan in the same period last year, a year-on-year decrease of 40.64%; the basic earnings per share were 0.2 yuan

Yili Chuanning Bio: In the first half of the year, the net profit attributable to the parent company was 455 million yuan, a year-on-year decrease of 40.64%

300553

On Friday, 12 companies had their restricted shares unlocked, with a total unlock volume of 20.3493 million shares and an unlock market value of 488 million yuan. WanYuanTong, JZABM, and Yili Chuanning Bio had the highest unlock volumes, at 6.2 million shares, 3.8268 million shares, and 2.925 million shares, respectively. The unlock market values for JZABM, WanYuanTong, and Yili Chuanning Bio were 185 million yuan, 185 million yuan, and 37.7325 million yuan, respectively. In terms of unlock ratios, JZABM, WanYuanTong, and Aili Home were 4.48%, 4.08%, and 0.93%, respectively

JZABM

Elegant

Overview of A-share restricted stock unlock: Restricted stocks worth 488 million yuan are unlocked today

301108

603630

000639

The A-share market adjusted with reduced volume today, with the ChiNext index falling nearly 2% at the close. Synthetic biology concept stocks rose against the trend, with Yili Chuanning Bio, JIEYA, and Meino Bio hitting the daily limit. The shipping sector surged and then retreated, while consumer stocks in food, clothing, and beauty care were active, with Xiwang Foodstuffs, Lafang, and Fengzhu Textile also hitting the daily limit. The military industry sector adjusted, with Tianjian Technology nearing the daily limit down, and computing power concept stocks weakened. The Shanghai Composite Index fell by 0.68%, the Shenzhen Component Index fell by 1.62%, and the ChiNext index fell by 1.92%

Wallstreetcn

JIEYA

Lafang

Xiwang Foodstuffs

NBOSCO

MENON

Fynex Textile

NBMC

Lianyungang Port

ChiNext

A-shares closing: The ChiNext index fell nearly 2% on reduced volume, while the synthetic biology concept surged against the trend

002626

603739

301089

Synthetic biology concept stocks fluctuated and rose, Yili Chuanning Bio hit a 20% limit up, Bawei Co., Ltd. rose over 20%, Tuoxin Pharmaceutical rose over 10%, Kingdomway, Ocon Pharmaceutical, and Vland Biotech followed suit

Kingdomway

Vland Biotech

Tuoxin Pharmaceutical

Synthetic biology concept stocks fluctuated and rose, Yili Chuanning Bio hit a 20% limit up

Yili Chuanning Bio announced that the operating revenue for 2024 is 5.758 billion yuan, a year-on-year increase of 19.38%. The net profit attributable to shareholders of the listed company is 1.4 billion yuan, a year-on-year increase of 48.88%. The basic earnings per share is 0.63 yuan/share, a year-on-year increase of 50.00%. The company plans to distribute a cash dividend of 2.7 yuan for every 10 shares to all shareholders, with 0 bonus shares, and to increase capital reserves by 0 shares for every 10 shares to all shareholders

Yili Chuanning Bio: 2024 net profit is expected to grow by 48.88% year-on-year

Yili Chuanning Bio(301301.SZ)